GNFT Fundamental Analysis - GENFIT-ADR

Name: GENFIT-ADR (GNFT) Stock
Brand: GENFIT-ADR
Rating: 6 (3 reviews)

Fundamental Rating

Taking everything into account, GNFT scores 2 out of 10 in our fundamental rating. GNFT was compared to 533 industry peers in the Biotechnology industry. Both the profitability and financial health of GNFT have multiple concerns. GNFT has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GNFT has reported negative net income.

In the past year GNFT has reported a negative cash flow from operations.

In multiple years GNFT reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.

1.2 Ratios

With a decent Return On Assets value of -17.89%, GNFT is doing good in the industry, outperforming 78.42% of the companies in the same industry.

GNFT's Return On Equity of -73.87% is in line compared to the rest of the industry. GNFT outperforms 55.16% of its industry peers.

		Industry Rank	Sector Rank
ROA	-17.89%
ROE	-73.87%
ROIC	N/A

ROA(3y)-8.87%

ROA(5y)-10.74%

ROE(3y)-21.81%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

In the last couple of years the Profit Margin of GNFT has declined.

In the last couple of years the Operating Margin of GNFT has declined.

GNFT has a better Gross Margin (95.42%) than 94.75% of its industry peers.

GNFT's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for GNFT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.42%

OM growth 3Y-50.59%

OM growth 5YN/A

PM growth 3Y-69.99%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for GNFT has been increased compared to 1 year ago.

The number of shares outstanding for GNFT has been increased compared to 5 years ago.

The debt/assets ratio for GNFT is higher compared to a year ago.

2.2 Solvency

GNFT has an Altman-Z score of -1.40. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.

GNFT has a Altman-Z score of -1.40. This is comparable to the rest of the industry: GNFT outperforms 55.35% of its industry peers.

A Debt/Equity ratio of 0.09 indicates that GNFT is not too dependend on debt financing.

The Debt to Equity ratio of GNFT (0.09) is worse than 63.04% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Altman-Z	-1.4

ROIC/WACCN/A

WACC7.23%

2.3 Liquidity

A Current Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.

GNFT's Current ratio of 3.74 is in line compared to the rest of the industry. GNFT outperforms 44.84% of its industry peers.

A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.

The Quick ratio of GNFT (3.74) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.74
Quick Ratio	3.74

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for GNFT have decreased strongly by -327.32% in the last year.

The earnings per share for GNFT have been decreasing by -70.77% on average. This is quite bad

Looking at the last year, GNFT shows a very negative growth in Revenue. The Revenue has decreased by -45.94% in the last year.

The Revenue has been growing by 11.61% on average over the past years. This is quite good.

EPS 1Y (TTM)-327.32%

EPS 3Y-70.77%

EPS 5YN/A

EPS Q2Q%-139.82%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-39.51%

3.2 Future

GNFT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.44% yearly.

GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.86% yearly.

EPS Next Y-110.7%

EPS Next 2Y-96.29%

EPS Next 3Y-45.26%

EPS Next 5Y-29.44%

Revenue Next Year-8.28%

Revenue Next 2Y-21.93%

Revenue Next 3Y-9.85%

Revenue Next 5Y-1.86%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

GNFT's earnings are expected to decrease with -45.26% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-96.29%

EPS Next 3Y-45.26%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GNFT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENFIT-ADR

NASDAQ:GNFT (11/19/2025, 2:00:00 PM)

4.85

+0.12 (+2.54%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-22 2025-09-22

Earnings (Next)11-20 2025-11-20

Inst Owners0.76%

Inst Owner Change-19.19%

Ins Owners0.18%

Ins Owner ChangeN/A

Market Cap242.51M

Revenue(TTM)45.41M

Net Income(TTM)-38.76M

Analysts90.77

Price Target10.06 (107.42%)

Short Float %0.05%

Short Ratio2.46

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.59%

PT rev (3m)-4.06%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-109.24%

EPS NY rev (3m)42.99%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-1.91%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	4.61
P/FCF	N/A
P/OCF	N/A
P/B	3.99
P/tB	98.48
EV/EBITDA	N/A

EPS(TTM)-0.89

EYN/A

EPS(NY)-0.78

Fwd EYN/A

FCF(TTM)-0.16

FCFYN/A

OCF(TTM)-0.08

OCFYN/A

SpS1.05

BVpS1.22

TBVpS0.05

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.89%
ROE	-73.87%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	95.42%
FCFM	N/A

ROA(3y)-8.87%

ROA(5y)-10.74%

ROE(3y)-21.81%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-50.59%

OM growth 5YN/A

PM growth 3Y-69.99%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

F-Score2

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	188.46%
Cap/Sales	7.33%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.74
Quick Ratio	3.74
Altman-Z	-1.4

F-Score2

WACC7.23%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-327.32%

EPS 3Y-70.77%

EPS 5YN/A

EPS Q2Q%-139.82%

EPS Next Y-110.7%

EPS Next 2Y-96.29%

EPS Next 3Y-45.26%

EPS Next 5Y-29.44%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-39.51%

Revenue Next Year-8.28%

Revenue Next 2Y-21.93%

Revenue Next 3Y-9.85%

Revenue Next 5Y-1.86%

EBIT growth 1Y-216.85%

EBIT growth 3Y-53.58%

EBIT growth 5YN/A

EBIT Next Year-6.17%

EBIT Next 3Y-0.9%

EBIT Next 5YN/A

FCF growth 1Y87.25%

FCF growth 3Y-47.27%

FCF growth 5YN/A

OCF growth 1Y93.33%

OCF growth 3Y-46.21%

OCF growth 5YN/A

GENFIT-ADR / GNFT FAQ

What is the fundamental rating for GNFT stock?

ChartMill assigns a fundamental rating of 2 / 10 to GNFT.

Can you provide the valuation status for GENFIT-ADR?

ChartMill assigns a valuation rating of 0 / 10 to GENFIT-ADR (GNFT). This can be considered as Overvalued.

Can you provide the profitability details for GENFIT-ADR?

GENFIT-ADR (GNFT) has a profitability rating of 2 / 10.

Can you provide the financial health for GNFT stock?

The financial health rating of GENFIT-ADR (GNFT) is 3 / 10.

GENFIT-ADR (GNFT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

GENFIT-ADR / GNFT FAQ

What is the fundamental rating for GNFT stock?

Can you provide the valuation status for GENFIT-ADR?

Can you provide the profitability details for GENFIT-ADR?

Can you provide the financial health for GNFT stock?